SOPH Stock Overview
SOPHiA GENETICS SA operates as a healthcare technology company.
SOPHiA GENETICS SA Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.65|
|52 Week High||US$18.24|
|52 Week Low||US$2.16|
|1 Month Change||-11.67%|
|3 Month Change||-27.60%|
|1 Year Change||-84.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-84.19%|
Recent News & Updates
SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
SOPHiA GENETICS (NASDAQ:SOPH) has entered a partnership with precision oncology company Boundless Bio to develop therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers. Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) as well as a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient's tumor sequencing data. SOPHiA (SOPH) said its ability to harmonize data derived from diverse genomic instruments combined with Boundless Bio's drug development capabilities can optimize patient selection and clinical trial design and support a network of hospitals and academic centers to deliver new treatment options for oncogene amplified cancers. SOPHiA (SOPH) also recently entered into an agreement with Memorial Sloan Kettering Cancer Center to allow its global network of healthcare providers access to MSK's proprietary tumor sequencing tests. Seeking Alpha's Quant Rating views SOPHiA (SOPH) as a hold with high marks for growth and valuation.
SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
SOPHiA Genetics press release (NASDAQ:SOPH): Q2 GAAP EPS of -$0.39 in-line. Revenue of $11.7M (+15.0% Y/Y) misses by $0.25M.
We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|SOPH||US Healthcare Services||US Market|
Return vs Industry: SOPH underperformed the US Healthcare Services industry which returned -51.9% over the past year.
Return vs Market: SOPH underperformed the US Market which returned -18.8% over the past year.
|SOPH Average Weekly Movement||13.2%|
|Healthcare Services Industry Average Movement||11.0%|
|Market Average Movement||7.0%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: SOPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SOPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.
SOPHiA GENETICS SA Fundamentals Summary
|SOPH fundamental statistics|
Is SOPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SOPH income statement (TTM)|
|Cost of Revenue||US$16.12m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.45|
|Net Profit Margin||-211.72%|
How did SOPH perform over the long term?See historical performance and comparison